Live
ScienceAncient wars between microbes gave us key immune defensesEndpoints NewsHow a group of biotechs ran a covert campaign to push out the FDA commissionerClinical OMICsOncology’s Next AI Battleground: Instant Clinical and Commercial InsightBioWorldAppointments and advancements for May 21, 2026BioWorldFinancings for May 21, 2026BioWorldIn the clinic for May 21, 2026BioWorldOther news to note for May 21, 2026BioWorldRegulatory actions for May 21, 2026BioPharma DiveRA Capital banks $75M for a biotech SPACEndpoints NewsChina’s drugmakers to take the stage at #ASCO26BioPharma DiveBioMarin notches win in study that could expand use of top-selling medicineFierceBiotechLilly’s triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile
BioPharma Dive Apr 6, 2026

Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout

Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout

Original
Body unavailable. Use the original source.